mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
ConditionEBV
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-25
SponsorVaccine Company, Inc.
About this trial
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Eligibility criteria
Qualifiers
Aged 18 to 25 years, inclusive
Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment
Disqualifiers
Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
Likely or confirmed myocarditis or pericarditis
Prior receipt of an investigational EBV vaccine
Prior receipt of a licensed vaccine within 56 days prior to Day 1
Trial design
Treatments tested in this trial
- VXCO-102
- Placebo
Treatment groups
45 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov